1-20 of 25 results for subject:Glaxo
Librarians' tools
- Search time
- 0.37 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Glaxo
- We searched for
- subject_t:Glaxo OR subject_ses:36599
Type
House
Session
Year
Department
Member
More
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Publisher
That this House expresses appreciation to the United Kingdom Prix Galien Awards for recognising the work of British scientists in the field of pharmaceutical research and development; and congratulates those people involved in the winning developments at Glaxo Wellcome and Roche Products UK who were honoured for their innovative work on lamotrigine, anti-epileptic drug, and saquinivir, Aids proteinase inhibitor.
That this House expresses appreciation to the United Kingdom Prix Galien Awards for recognising the work of British scientists in the field of pharmaceutical research and development; and congratulates those people involved in the winning developments at Glaxo Wellcome and Roche Products UK who were honoured for their innovative work...
Adjournment debate on Glaxo-Wellcome site in Beckenham.
Adjournment debate on Glaxo-Wellcome site in Beckenham.
That this House notes the take-over bid by Glaxo for Wellcome; recognises the important role both companies have played in putting the United Kingdom amongst the leaders in the world pharmaceutical industry; is concerned at this recent turn of events and in particular the significant job losses which will undoubtedly occur as a consequence of streamlining research and development programmes, rationalising manufacturing facilities and reshaping the selling and administrative functions; criticises the decision of the Wellcome Trust to dispose of its total shareholding in Wellcome without apparent regard for the longstanding relationship between the Trust and the company or without obtaining assurances about the long-term interests of the employees at Wellcome; and calls upon Her Majesty's Government to develop an effective industrial strategy for the pharmaceutical industry which encourages co-operation and joint ventures for the benefit of all and avoids the distracting and damaging consequences of leaving the future of major United Kingdom companies entirely in the hands of the financial markets. (Relevant registered interest declared).
That this House notes the take-over bid by Glaxo for Wellcome; recognises the important role both companies have played in putting the United Kingdom amongst the leaders in the world pharmaceutical industry; is concerned at this recent turn of events and in particular the significant job losses which will undoubtedly...
What consideration he has given to the long term effect on research and development of the proposed takeover of Wellcome by Glaxo.
What consideration he has given to the long term effect on research and development of the proposed takeover of Wellcome by Glaxo.
If he will hold an urgent investigation into the legal aid position for those suffering from arachnoiditis following treatment by Myodil and who are seeking compensation from Glaxo. - No. Decisions on individual legal aid applications are entirely a matter for legal aid board.
If he will hold an urgent investigation into the legal aid position for those suffering from arachnoiditis following treatment by Myodil and who are seeking compensation from Glaxo. - No. Decisions on individual legal aid applications are entirely a matter for legal aid board.
What action she is taking to help those suffering from arachnoiditis following treatment by Myodil used in spinal investigations to claim compensation from Glaxo.
What action she is taking to help those suffering from arachnoiditis following treatment by Myodil used in spinal investigations to claim compensation from Glaxo.
In what circumstances Glaxo plc will not have to pay the full agreed price to the Exchequer in respect of its acquisition of the site of the Warren Springs Laboratory at Welwyn.
In what circumstances Glaxo plc will not have to pay the full agreed price to the Exchequer in respect of its acquisition of the site of the Warren Springs Laboratory at Welwyn.